Three Months Treatment With SB683699 In Patients With Relapsing Multip
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Investigate the Efficacy and Safety of Three Months Administration of SB-683699 (150 - 1200mg Twice Daily) in Subjects With Relapsing Multiple Sclerosis
What it found
We found no results in the registry or in papers.
This trial finished 20 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- SB683699
- NA
What it measured
Main measures
Number of new gadolinium-enhancing lesions on monthly MRI scans
MRI lesions
Other measures (5)
Number of other lesion types on MRI
MRI lesionsNumber of relapses during treatment
RelapsesExpanded Disability Status Scale (EDSS) and MS Functional Composite (MSFC)
Disability progressionCirculating lymphocyte and neutrophil counts
Immune responseHealth Outcomes: MSIS-29, Employment status
Quality of life (reported by participants)
Who could take part
Relapsing MS · 18 to 65
Show the full criteria
Inclusion criteria
* Diagnosis of multiple sclerosis (MS). * Expanded Disability Status Score 0 - 6.5. * One or more relapse of MS in previous 12 months. * Currently not taking any medications for MS (apart from those used to treat symptoms).
Exclusion criteria
* Patients with significantly abnormal laboratory tests or electrocardiogram (ECG) results. * Subjects who cannot have MRI scans. * Women who are pregnant, breast feeding or planning to become pregnant during the study.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The study will evaluate the effectiveness and safety of the investigational drug SB683699 in treating patients with relapsing multiple sclerosis (MS), using data from magnetic resonance imaging (MRI) scans as the main measure.
Papers
Loading reviews and guidelines…
History
Started
Sept 2004
Main results due
Jul 2006
Finished
Jul 2006